The purpose of this study is to evaluate body composition across a variety of medical, professional, and commercial devices, including: bioelectrical impedance analysis (BIA) devices, 3-dimensional optical imaging (3DO), manual anthropometry measurements, dual-energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), and blood tests. The secondary study purpose is to compare body composition measurements from BIA devices, 3DO, and manual anthropometry measurements within a 1-week period for a subset of the study population.
The study plans to enroll 300 healthy (having no life-threatening conditions or diseases; male and female) participants, 18 years of age or older.
Being willing to provide written informed consent prior to participation Being willing to complete the study visits and comply with the study procedures
Being willing to travel to the various study locations for On-site, DXA, MRI, and Phlebotomy visits
Being willing to change into appropriate form-fitting clothing for 3DO assessments and/or appropriate gowns for DXA and MRI imaging
Must have a BMI within the range of 18.5 - 45 kg/m2
Being pregnant or attempting to become pregnant
Having medical implants, such as a pacemaker or metal joint replacements, or other metal implants contraindicated for MRI
Cosmetic implants, such as breast implants
Having a height greater than DXA scanning limit (77 inches)
A diverse sample of adults will be recruited for participation in the US. Stratification will occur based on sex and BMI, with additional targets to promote recruitment of a variety of ages and adequate representation of racial and ethnic categories. For race and ethnicity, the goal will be to obtain a distribution approximately equal to the demographics of the United States, with selective oversampling employed as needed. For BMI, the following percentages will be used as approximate goals for the sample (18.50-19.99, None; 20.00-24.99, 20%; 25.00-29.99, 35%; 30.00-34.99, 25%; 35.00-39.99, 13.30%; 40.00-44.99, 6.70%; ≥45, None). However, the distribution of BMI and other demographic characteristics will be monitored as the study progresses in case adjustment is needed.
Cohort
Prospective
Not listed
Modality-reference agreement for total fat mass (kg)
Agreement between bioimpedance and 3-dimensional optical imaging derived estimates of total fat mass and DXA-derived reference measurements.
Modality-reference agreement for fat-free mass (kg)
Agreement between bioimpedance and 3-dimensional optical imaging derived estimates of fat-free mass and DXA-derived reference measurements.
Modality-reference agreement for percent body fat (%)
Agreement between bioimpedance and 3-dimensional optical imaging derived estimates of percent body fat and DXA-derived reference measurements.
Modality-reference agreement for visceral adipose tissue (VAT; kg or volume)
Agreement between bioimpedance and 3-dimensional optical imaging derived estimates of visceral adipose tissue and MRI-derived reference measurements.
Agreement of blood-based proteomics-derived fat-free mass with DXA-derived fat-free mass (kg)
Agreement between blood-based proteomics-derived fat-free mass and DXA-derived fat-free mass, assessed using the prespecified agreement analyses.
Agreement of blood-based proteomics-derived total fat mass with DXA-derived total fat mass (kg)
Description: Agreement between blood-based proteomics-derived total fat mass and DXA-derived total fat mass, assessed using the prespecified agreement analyses.
Agreement of blood-based proteomics-derived percent body fat with DXA-derived percent body fat (%)
Agreement between blood-based proteomics-derived percent body fat and DXA-derived percent body fat, assessed using the prespecified agreement analyses.
Agreement of blood-based proteomics-derived visceral adipose tissue with MRI-derived visceral adipose tissue
Agreement between blood-based proteomics-derived visceral adipose tissue and MRI-derived visceral adipose tissue, assessed using the prespecified agreement analyses
Click on the lead sponsor to view all of their trials.
Foundation for the National Institutes of Health
Lead sponsor
Exponent, Inc.
Collaborator
Pennington Biomedical Research Center
Collaborator
Texas Tech University
Collaborator
